Melanoma antigens and targets for vaccination

British Journal of Hospital Medicine

Volumn 58, Issue 6, 1997, Pages 282-286

  Kang, Norbert ^a   Truman, Hazel ^a   Sanders, Roy ^a   Kupsch, Jörg ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; DRUG DESIGN; HUMAN; IMMUNOLOGY; MELANOMA; METASTASIS; REVIEW; SKIN TUMOR; SURVIVAL RATE;

ANTIGENS, NEOPLASM; CANCER VACCINES; DRUG DESIGN; HUMANS; IMMUNOTHERAPY, ACTIVE; MELANOMA; NEOPLASM METASTASIS; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 0031576108     PISSN: 00071064     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Balch CM, Soong S-J, Murad TM et al (1981) A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node métastases (stage II). Ann Surg 193:377
2. Boon T, Ga)ewski TF, Coulie PG (1995) From defined human tumour antigens to effective immunisation? Immunol Today 16: 334-5
3. Chapman PB, Houghton AN (1991) Induction of IgG antibodies against GD3 gangliosides in rabbits by an anti-idiotypic monoclonal antibody J Clin Invest 88: 186-92
4. Colombo MP, Form G (1995) Cytokine gene transfer in tumour inhibition and tumour therapy: where are we now? Immunol Today 15: 48-51
5. Everson T, Cole W (1966) Spontaneous Regression of Cancer. WB Saunders, Philadelphia: 164
6. Fagcrberg I, Hjelm AL, Ragnhammar P, Frödin JE, Wigzell H, Mellstedt H (1995) Tumour regression in monoclonal antibody-treated patients correlates with the presence of antiidiotype-reactive T lymphocytes. Cancer Res 55: 1824-7
7. Gately'MK, Gubler U, Brunda MJ et al (1994) Interleukin-12: a cytokme with therapeutic potential in oncology and infectious diseases. Therapeutic Immunol 1: 187-96
8. Helling F, Zhang S, Shang A et al (1995) GM2-KLH conjugate vaccine: Increased immunogemcity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 55: 2783-8
9. Jones VE, Mitchell MS (1996) Therapeutic vaccines for melanoma: progress and problems. TIBTECH 14: 349-55
10. Kawakami Y, Robbins PF, Rosenberg SA (1996) Human melanoma antigens recognized by T lymphocytes. Keio J Med 45: 100-8
11. Kupsch JM, Tidman N, Newton Bishop JA et al (1995) Generation and selection of monoclonal antibodies, singlechain Fv and antibody fusion phage specific for human melanoma-associated antigens. Melanoma Res 5: 403-11
12. Mastrangelo MJ, Maguire HC, Sato T, Nathan FE, Berd D (1996) Active specific immunisation in the treatment of patients with melanoma. Semin Owcol 23: 773-81
13. Mittelman A, Chen ZJ, Liu CC, Hirai S, Ferrone S (1994) Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with anti-idiotypic monoclonal antibody MK2-23. Cancer Res 54: 4\5-21
14. Mittelman A, Wang X, Matsumoto K, Ferrone S (1995) Antianti-idiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse anti-idiotypic monoclonal antibody MK2-23. Hybridoma 14: 175-81
15. Mukherji B, Chakraborty NG, Yamasaki S et al (1995) Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunisation with synthetic peptidepulsed autologous antigen presenting cells. Proc Natl Acad Sei USA 92: 8078-82
16. Ostrand-Rosenberg S (1994) Tumour immunotherapy; the tumour cell as an antigen-presenting cell. Gurr Opin Immunol 6: 722-7
17. Parmiani G, Colombo MP (1995) Somatic gene therapy of human melanoma: pre-clinical studies and early clinical trials. Melanoma Res 5: 295-301
18. Rosenthal FM, Zier KS Gansbacher B (1994) Human tumour vaccines and genetic engineering of tumours with cytokine and histocompatibihty genes to enhance immunogenicity. Curr Opin Oncol 6: 611-15
19. Shoenfeld Y, Amital H, Ferrone S, Kennedy RC (1994) Antiidiotypes and their application under autoimmune, neoplastic, and infectious conditions. Int Arch Allergy Immunol 105:211-23
20. Tefany FJ, Barnetson RS, Halliday GM et al (1991) Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. 7 Invest Dermatol 97: 197